1
|
Hui J, Zhu Y, Sze D, Lowe A, Wang D. Abstract No. 272 Selective Hepatic Vein Sampling for Enriched Circulating Tumor Cell Collection in Patients with Liver Dominant Malignancy—Preliminary Results. J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
2
|
Hund H, Du L, Matsuoka L, Sze D, Kennedy A, Vaheesan K, Petroziello M, Golzarian J, Wang E, Ghandi R, Collins Z, Brower J, Lee J, Brown D. Abstract No. 79 Comparison of 90Y Radioembolization Outcomes for Hepatocellular Carcinoma (HCC) in TACE-Refractory (T-REF) vs Treatment Naïve (TN) Patients in the RESiN Registry (NCT: 02685631). J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
3
|
Biehl A, Gracioso Martins AM, Davis ZG, Sze D, Collins L, Mora-Navarro C, Fisher MB, Freytes DO. Towards a standardized multi-tissue decellularization protocol for the derivation of extracellular matrix materials. Biomater Sci 2023; 11:641-654. [PMID: 36504129 PMCID: PMC9844390 DOI: 10.1039/d2bm01012g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 11/21/2022] [Indexed: 12/14/2022]
Abstract
The goal of tissue decellularization is to efficiently remove unwanted cellular components, such as DNA and cellular debris, while retaining the complex structural and molecular milieu within the extracellular matrix (ECM). Decellularization protocols to date are centered on customized tissue-specific and lab-specific protocols that involve consecutive manual steps which results in variable and protocol-specific ECM material. The differences that result from the inconsistent protocols between decellularized ECMs affect consistency across batches, limit comparisons between results obtained from different laboratories, and could limit the transferability of the material for consistent laboratory or clinical use. The present study is the first proof-of-concept towards the development of a standardized protocol that can be used to derive multiple ECM biomaterials (powders and hydrogels) via a previously established automated system. The automated decellularization method developed by our group was used due to its short decellularization time (4 hours) and its ability to reduce batch-to-batch variability. The ECM obtained using this first iteration of a unified protocol was able to produce ECM hydrogels from skin, lung, muscle, tendons, cartilage, and laryngeal tissues. All hydrogels formed in this study were cytocompatible and showed gelation and rheological properties consistent with previous ECM hydrogels. The ECMs also showed unique proteomic composition. The present study represents the first step towards developing standardized protocols that can be used on multiple tissues in a fast, scalable, and reproducible manner.
Collapse
Affiliation(s)
- Andreea Biehl
- Joint Department of Biomedical Engineering, North Carolina State University & University of North Carolina-Chapel Hill, 4130 Engineering Building III, Campus Box 7115, Raleigh, NC 27695, USA.
- Comparative Medicine Institute, North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27606, USA
| | - Ana M Gracioso Martins
- Joint Department of Biomedical Engineering, North Carolina State University & University of North Carolina-Chapel Hill, 4130 Engineering Building III, Campus Box 7115, Raleigh, NC 27695, USA.
- Comparative Medicine Institute, North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27606, USA
| | - Zachary G Davis
- Joint Department of Biomedical Engineering, North Carolina State University & University of North Carolina-Chapel Hill, 4130 Engineering Building III, Campus Box 7115, Raleigh, NC 27695, USA.
- Comparative Medicine Institute, North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27606, USA
| | - Daphne Sze
- Joint Department of Biomedical Engineering, North Carolina State University & University of North Carolina-Chapel Hill, 4130 Engineering Building III, Campus Box 7115, Raleigh, NC 27695, USA.
- Comparative Medicine Institute, North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27606, USA
| | - Leonard Collins
- Molecular Education, Technology and Research Innovation Center (METRIC), North Carolina State University, Dabney Hall, 2620 Yarbrough Drive, Raleigh, NC 27607, USA
| | - Camilo Mora-Navarro
- Department of Chemical Engineering, University of Puerto Rico-Mayaguez, Route 108, Mayaguez, Puerto Rico, USA
| | - Matthew B Fisher
- Joint Department of Biomedical Engineering, North Carolina State University & University of North Carolina-Chapel Hill, 4130 Engineering Building III, Campus Box 7115, Raleigh, NC 27695, USA.
- Comparative Medicine Institute, North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27606, USA
- Department of Orthopaedics, University of North Carolina School of Medicine, 102 Mason Farm Road Second Floor, Chapel Hill, NC 27514, USA
| | - Donald O Freytes
- Joint Department of Biomedical Engineering, North Carolina State University & University of North Carolina-Chapel Hill, 4130 Engineering Building III, Campus Box 7115, Raleigh, NC 27695, USA.
- Comparative Medicine Institute, North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27606, USA
| |
Collapse
|
4
|
Emmons E, Krebs H, Gandhi R, Collins Z, O’Hara R, Akhter N, Wang E, Grilli C, Brower J, Peck S, Petroziello M, Aal AA, Golzarian J, Kennedy A, Matsuoka L, Sze D, Brown D. Abstract No. 1 ▪ ABSTRACT OF THE YEAR Survival outcomes and toxicities following Y-90 radioembolization of colorectal cancer metastatic to the liver: 498-patient analysis from the RESiN registry (NCT: 02685631). J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
5
|
Goswami P, Adeniran O, Frantz S, Matsuoka L, Du L, Gandhi R, Collins Z, Matrana M, Petroziello M, Brower J, Sze D, Kennedy A, Golzarian J, Wang E, Brown D. Abstract No. 196 Overall survival and toxicities of advanced hepatocellular carcinoma (HCC) Barcelona clinic liver cancer C (BCLC-C) patients following Y-90 radioembolization: assessment from the RESiN Registry (NCT: 02685631). J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
6
|
Robinson T, Zhang K, Matsuoka L, Sze D, Kennedy A, Gandhi R, Kouri B, Collins Z, O’Hara R, Kokabi N, Grilli C, Wang E, Lee J, Brown D. Abstract No. 304 Evaluation of survival and toxicity of cholangiocarcinoma treated with Y-90 radioembolization: outcomes assessment from the radiation emitting SIR-Spheres in non-resectable tumor registry. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
7
|
Mead BE, Hattori K, Levy L, Imada S, Goto N, Vukovic M, Sze D, Kummerlowe C, Matute JD, Duan J, Langer R, Blumberg RS, Ordovas-Montanes J, Yilmaz ÖH, Karp JM, Shalek AK. Screening for modulators of the cellular composition of gut epithelia via organoid models of intestinal stem cell differentiation. Nat Biomed Eng 2022; 6:476-494. [PMID: 35314801 PMCID: PMC9046079 DOI: 10.1038/s41551-022-00863-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 02/03/2022] [Indexed: 12/12/2022]
Abstract
The cellular composition of barrier epithelia is essential to organismal homoeostasis. In particular, within the small intestine, adult stem cells establish tissue cellularity, and may provide a means to control the abundance and quality of specialized epithelial cells. Yet, methods for the identification of biological targets regulating epithelial composition and function, and of small molecules modulating them, are lacking. Here we show that druggable biological targets and small-molecule regulators of intestinal stem cell differentiation can be identified via multiplexed phenotypic screening using thousands of miniaturized organoid models of intestinal stem cell differentiation into Paneth cells, and validated via longitudinal single-cell RNA-sequencing. We found that inhibitors of the nuclear exporter Exportin 1 modulate the fate of intestinal stem cells, independently of known differentiation cues, significantly increasing the abundance of Paneth cells in the organoids and in wild-type mice. Physiological organoid models of the differentiation of intestinal stem cells could find broader utility for the screening of biological targets and small molecules that can modulate the composition and function of other barrier epithelia.
Collapse
Grants
- R01 DK088199 NIDDK NIH HHS
- Howard Hughes Medical Institute
- P30 CA014051 NCI NIH HHS
- DP2 GM119419 NIGMS NIH HHS
- R01 DE013023 NIDCR NIH HHS
- P30 DK034854 NIDDK NIH HHS
- R01 HL095722 NHLBI NIH HHS
- T32 GM087237 NIGMS NIH HHS
- R01 CA034992 NCI NIH HHS
- R01 CA211184 NCI NIH HHS
- U54 CA217377 NCI NIH HHS
- INV-006897 Bill & Melinda Gates Foundation
- The National Science Foundation graduate research fellowship program and the Massachusetts Institute of Technology – GlaxoSmithKline (MIT-GSK) Gertrude B. Elion Postdoctoral fellowship.
- Fellowships from The Japanese Biochemical Society (The Osamu Hayaishi Memorial Scholarship for Study Abroad), Mochida Memorial Foundation for Medical and Pharmaceutical Research, and The Uehara Memorial Foundation.
- NIH (DE013023)
- NIH (DK088199)
- New York Stem Cell Foundation – Robertson Investigator, the Richard and Susan Smith Family Foundation, the HHMI Damon Runyon Cancer Research Foundation Fellowship (DRG-2274-16), the AGA Research Foundation’s AGA-Takeda Pharmaceuticals Research Scholar Award in IBD – AGA2020-13-01, the HDDC Pilot and Feasibility P30 DK034854, the Food Allergy Science Initiative, and The New York Stem Cell Foundation.
- NIH (R01CA211184, R01CA034992); Pew-Stewart Trust scholar award; the Kathy and Curt Marble Cancer Research Award; a Bridge grant; and the MIT Stem Cell Initiative through Fondation MIT.
- the Kenneth Rainin Foundation Innovator and Breakthrough awards, the Crohn’s and Colitis Foundation (#624458),the NIH (HL095722), and the Harvard Digestive Disease Center and NIH grant P30DK034854.
- the Beckman Young Investigator Program, the Pew-Stewart Scholars Program for Cancer Research, a Sloan Fellowship in Chemistry, the NIH (1DP2GM119419, 1U54CA217377), the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute, and the MIT Stem Cell Initiative through Fondation MIT.
Collapse
Affiliation(s)
- Benjamin E Mead
- Harvard-MIT Program in Health Sciences and Technology, MIT, Cambridge, MA, USA
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
- Harvard Stem Cell Institute, Cambridge, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Institute for Medical Engineering and Science, MIT, Cambridge, MA, USA
- Department of Chemistry, MIT, Cambridge, MA, USA
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
| | - Kazuki Hattori
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
- Harvard Stem Cell Institute, Cambridge, MA, USA
- Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Lauren Levy
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
- Harvard Stem Cell Institute, Cambridge, MA, USA
- Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Shinya Imada
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
| | - Norihiro Goto
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
| | - Marko Vukovic
- Harvard-MIT Program in Health Sciences and Technology, MIT, Cambridge, MA, USA
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
- Harvard Stem Cell Institute, Cambridge, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Institute for Medical Engineering and Science, MIT, Cambridge, MA, USA
- Department of Chemistry, MIT, Cambridge, MA, USA
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
- Division of Gastroenterology Boston Children's Hospital, Program in Immunology, Harvard Medical School, Boston, MA, USA
| | - Daphne Sze
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
- Harvard Stem Cell Institute, Cambridge, MA, USA
- Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Conner Kummerlowe
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
- Harvard Stem Cell Institute, Cambridge, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Institute for Medical Engineering and Science, MIT, Cambridge, MA, USA
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
| | - Juan D Matute
- Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Division of Neonatology, Department of Pediatrics, MGH Harvard Medical School, Boston, MA, USA
| | - Jinzhi Duan
- Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Robert Langer
- Harvard-MIT Program in Health Sciences and Technology, MIT, Cambridge, MA, USA
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
- Institute for Medical Engineering and Science, MIT, Cambridge, MA, USA
- Department of Chemical Engineering, MIT, Cambridge, MA, USA
| | - Richard S Blumberg
- Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Jose Ordovas-Montanes
- Harvard Stem Cell Institute, Cambridge, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Division of Gastroenterology Boston Children's Hospital, Program in Immunology, Harvard Medical School, Boston, MA, USA
| | - Ömer H Yilmaz
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA
- Department of Pathology, MGH, Harvard Medical School, Boston, MA, USA
| | - Jeffrey M Karp
- Harvard-MIT Program in Health Sciences and Technology, MIT, Cambridge, MA, USA.
- Harvard Stem Cell Institute, Cambridge, MA, USA.
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
| | - Alex K Shalek
- Harvard-MIT Program in Health Sciences and Technology, MIT, Cambridge, MA, USA.
- Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
- Harvard Stem Cell Institute, Cambridge, MA, USA.
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Institute for Medical Engineering and Science, MIT, Cambridge, MA, USA.
- Department of Chemistry, MIT, Cambridge, MA, USA.
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
| |
Collapse
|
8
|
Gracioso Martins AM, Biehl A, Sze D, Freytes DO. Bioreactors for Vocal Fold Tissue Engineering. Tissue Eng Part B Rev 2022; 28:182-205. [PMID: 33446061 PMCID: PMC8892964 DOI: 10.1089/ten.teb.2020.0285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
It is estimated that almost one-third of the United States population will be affected by a vocal fold (VF) disorder during their lifespan. Promising therapies to treat VF injury and scarring are mostly centered on VF tissue engineering strategies such as the injection of engineered biomaterials and cell therapy. VF tissue engineering, however, is a challenging field as the biomechanical properties, structure, and composition of the VF tissue change upon exposure to mechanical stimulation. As a result, the development of long-term VF treatment strategies relies on the characterization of engineered tissues under a controlled mechanical environment. In this review, we highlight the importance of bioreactors as a powerful tool for VF tissue engineering with a focus on the current state of the art of bioreactors designed to mimic phonation in vitro. We discuss the influence of the phonatory environment on the development, function, injury, and healing of the VF tissue and its importance for the development of efficient therapeutic strategies. A concise and comprehensive overview of bioreactor designs, principles, operating parameters, and scalability are presented. An in-depth analysis of VF bioreactor data to date reveals that mechanical stimulation significantly influences cell viability and the expression of proinflammatory and profibrotic genes in vitro. Although the precision and accuracy of bioreactors contribute to generating reliable results, diverse gene expression profiles across the literature suggest that future efforts should focus on the standardization of bioreactor parameters to enable direct comparisons between studies. Impact statement We present a comprehensive review of bioreactors for vocal fold (VF) tissue engineering with a focus on the influence of the phonatory environment on the development, function, injury, and healing of the VFs and the importance of mimicking phonation on engineered VF tissues in vitro. Furthermore, we put forward a strong argument for the continued development of bioreactors in this area with an emphasis on the standardization of bioreactor designs, principles, operating parameters, and oscillatory regimes to enable comparisons between studies.
Collapse
Affiliation(s)
- Ana M Gracioso Martins
- Joint Department of Biomedical Engineering, College of Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina, USA.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA
| | - Andreea Biehl
- Joint Department of Biomedical Engineering, College of Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina, USA.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA
| | - Daphne Sze
- Joint Department of Biomedical Engineering, College of Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina, USA.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA
| | - Donald O Freytes
- Joint Department of Biomedical Engineering, College of Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina, USA.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA
| |
Collapse
|
9
|
Frantz S, Matsuoka L, Shahin I, Vaheesan K, Petroziello M, D’Souza D, Golzarian J, Matrana M, Wang E, Gandhi R, Collins Z, Brower J, Du, Kennedy A, Sze D, Lee J, Adeniran O, Wong T, O’Hara R, Fidelman N, Shrestha R, Kouri B, Hennemeyer C, Meek J, Mohan P, Westcott M, Siskin G, Brown D. Abstract No. 115 Demographics and outcomes following Y90 radioembolization of hepatocellular carcinoma at transplant versus non-transplant centers: analysis of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. J Vasc Interv Radiol 2021. [DOI: 10.1016/j.jvir.2021.03.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
10
|
Mora-Navarro C, Ozpinar EW, Sze D, Martin DP, Freytes DO. Transcriptome-targeted analysis of human peripheral blood-derived macrophages when cultured on biomaterial meshes. Biomed Mater 2021; 16:025006. [PMID: 33445160 DOI: 10.1088/1748-605x/abdbdb] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Surgical meshes are commonly used to repair defects and support soft tissues. Macrophages (Mφs) are critical cells in the wound healing process and are involved in the host response upon foreign biomaterials. There are various commercially available permanent and absorbable meshes used by surgeons for surgical interventions. Polypropylene (PP) meshes represent a permanent biomaterial that can elicit both inflammatory and anti-inflammatory responses. In contrast, poly-4-hydroxybutyrate (P4HB) based meshes are absorbable and linked to positive clinical outcomes but have a poorly characterized immune response. This study evaluated the in vitro targeted transcriptomic response of human Mφs seeded for 48 h on PP and P4HB surgical meshes. The in vitro measured response from human Mφs cultured on P4HB exhibited inflammatory and anti-inflammatory gene expression profiles typically associated with wound healing, which aligns with in vivo animal studies from literature. The work herein provides in vitro evidence for the early transcriptomic targeted signature of human Mφs upon two commonly used surgical meshes. The findings suggest a transition from an inflammatory to a non-inflammatory phenotype by P4HB as well as an upregulation of genes annotated under the pathogen response pathway.
Collapse
Affiliation(s)
- Camilo Mora-Navarro
- The Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina-Chapel Hill, 4208D Engineering Building III, Raleigh, NC, United States of America. The Comparative Medicine Institute, North Carolina State University, Raleigh, NC, United States of America
| | | | | | | | | |
Collapse
|
11
|
Badileanu A, Mora-Navarro C, Gracioso Martins AM, Garcia ME, Sze D, Ozpinar EW, Gaffney L, Enders JR, Branski RC, Freytes DO. Fast Automated Approach for the Derivation of Acellular Extracellular Matrix Scaffolds from Porcine Soft Tissues. ACS Biomater Sci Eng 2020; 6:4200-4213. [PMID: 33463339 DOI: 10.1021/acsbiomaterials.0c00265] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Decellularized extracellular matrix (ECM) scaffolds derived from tissues and organs are complex biomaterials used in clinical and research applications. A number of decellularization protocols have been described for ECM biomaterials derivation, each adapted to a particular tissue and use, restricting comparisons among materials. One of the major sources of variability in ECM products comes from the tissue source and animal age. Although this variability could be minimized using established tissue sources, other sources arise from the decellularization process itself. Overall, current protocols require manual work and are poorly standardized with regard to the choice of reagents, the order by which they are added, and exposure times. The combination of these factors adds variability affecting the uniformity of the final product between batches. Furthermore, each protocol needs to be optimized for each tissue and tissue source making tissue-to-tissue comparisons difficult. Automation and standardization of ECM scaffold development constitute a significant improvement to current biomanufacturing techniques but remains poorly explored. This study aimed to develop a biofabrication method for fast and automated derivation of raw material for ECM hydrogel production while preserving ECM composition and controlling lot-to-lot variability. The main result was a closed semibatch bioreactor system with automated dosing of decellularization reagents capable of deriving ECM material from pretreated soft tissues. The ECM was further processed into hydrogels to demonstrate gelation and cytocompatibility. This work presents a versatile, scalable, and automated platform for the rapid production of ECM scaffolds.
Collapse
Affiliation(s)
- Andreea Badileanu
- Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina 27695, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Camilo Mora-Navarro
- Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina 27695, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Ana M Gracioso Martins
- Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina 27695, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Mario E Garcia
- Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina 27695, United States
| | - Daphne Sze
- Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina 27695, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Emily W Ozpinar
- Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina 27695, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Lewis Gaffney
- Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina 27695, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Jeffrey R Enders
- Molecular Education, Technology and Research Innovation Center, North Carolina State University, Raleigh, North Carolina 27695, United States.,The Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Ryan C Branski
- Departments of Rehabilitation Medicine, Otolaryngology-Head and Neck Surgery, and Pathology, New York University Grossman School of Medicine, New York, New York 10003, United States
| | - Donald O Freytes
- Joint Department of Biomedical Engineering, North Carolina State University/University of North Carolina-Chapel Hill, Raleigh, North Carolina 27695, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina 27695, United States
| |
Collapse
|
12
|
Dendy Case M, Ghodadra A, Novelli P, Wu V, Ganguli S, Wildgruber M, Kohler M, Robinson C, Kim C, Wang D, Sze D, Kolbeck K, Russell L, Ludwig J, Uhlig J, Kim K. 3:45 PM Abstract No. 27 Neutrophil-lymphocyte ratio correlates with survival in MUlticenter Study of RAS Mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
13
|
O’Malley M, Idakoji I, Louie J, Sze D, Wang D. 03:18 PM Abstract No. 270 Parallel TIPS versus DIPS for second percutaneous portosystemic shunt placement in cirrhotic patients with an existing TIPS. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
14
|
Litton E, Bass F, Delaney A, Hillis G, Marasco S, McGuinness S, Myles PS, Reid CM, Smith JA, Bagshaw SM, Keri-Anne Cowdrey HB, Frengley R, Ferrier J, Gilder E, Henderson S, Larobina M, Merthens J, Morgan M, Navarra L, Rudas M, Turner L, Reid K, Wise M, Young N, Young P, McGiffin D, Duncan J, Kaczmarek M, Seevanayagam S, Shaw M, Shardey G, Skillington P, Chorley T, Baker L, Zhang B, Bright C, Baker R, Canning N, Gilfillan, Kruger R, Fayers T, Kyte M, Doran C, Smith J, Baxter H, Seah P, Scaybrook S, James A, Goodwin K, Dignan R, Hewitt N, Gerrard K, Curtis L, Smith J, Baxter H, Tiruvoipati R, Broukal N, Wolfenden H, Muir, Worthington M, Wong C, Tatoulis J, Wynne R, Marshman D, Sze D, Wilson M, Turner L, Passage J, Kolybaba M, Fermanis G, Newbon P, Passage J, Kolybaba M, Newcomb A, Mack J, Duve K, Jansz P, Hunter T, Bissaker P, Dennis N, Burke N, Yadav S, Cooper K, Chard R, Halaka M, Tran L, Huq M, Billah B, Reid CM. Six-Month Outcomes After High-Risk Coronary Artery Bypass Graft Surgery and Preoperative Intra-aortic Balloon Counterpulsation Use: An Inception Cohort Study. J Cardiothorac Vasc Anesth 2018; 32:2067-2073. [DOI: 10.1053/j.jvca.2018.01.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Indexed: 11/11/2022]
|
15
|
Abdelmaksoud M, Abuelsalheen O, Ibrahim K, AbdelRazek M, Abdelfattah A, Abdelaziz A, Darwish A, Hassanien M, Ismail A, Hosny A, Hazem A, Sami A, Fattah Y, Sze D. 3:09 PM Abstract No. 122 Lobar or whole-liver Yttrium-90 radioembolization using resin microspheres without prophylactic embolization of the gastroduodenal artery. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
16
|
Fletcher W, Louie J, Kothary N, Wang D, Sze D. Abstract No. 516 Treatment of parasitized gastric arteries supplying hepatic tumors. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
17
|
AbdelRazek M, Khalaf M, Abdelmaksoud M, Lam M, Wang D, Louie J, Sze D. 3:27 PM Abstract No. 124 MIRD-based activity calculation may improve outcomes over body surface area for resin microsphere radioembolization of metastatic colorectal carcinoma. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.141] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
18
|
Cohn D, Arendt V, Jeon G, An X, Kuo W, Sze D, Rubin D, Hofmann L. 3:54 PM Abstract No. 357 Venous stenting above versus below the inguinal ligament: 20-year experience. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
19
|
Hoang N, Khalaf M, Reposar A, Kwofie J, Sze D. 3:36 PM Abstract No. 145 Quantification of activity lost to delivery-system residual and decay in Yttrium-90 radioembolization. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
20
|
Abdou M, Sze D, Wong C, Sawan M, Ying A, Morley NB, Malang S. U.S. Plans and Strategy for ITER Blanket Testing. Fusion Science and Technology 2017. [DOI: 10.13182/fst05-a732] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Abdou
- UCLA Fusion Engineering Sciences, Los Angeles, CA
| | - D. Sze
- UCSD Advanced Energy Technology Group, San Diego, CA
| | - C. Wong
- General Atomics, San Diego, CA
| | - M. Sawan
- University of Wisconsin Fusion Technology Institute, Madison, WI
| | - A. Ying
- UCLA Fusion Engineering Sciences, Los Angeles, CA
| | - N. B. Morley
- UCLA Fusion Engineering Sciences, Los Angeles, CA
| | - S. Malang
- Consultant, Fliederweg 3, D 76351 Linkenheim-Hochstetten, Germany
| |
Collapse
|
21
|
Laidlaw G, Wang D, Sze D, Hwang G, Louie J. Clinical toxicity of irinotecan-eluting microsphere TACE for colorectal cancer hepatic metastases: oncozene versus LC bead. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
22
|
AbdelRazek M, Hwang W, Abdelmaksoud M, Louie J, Kothary N, Kunz P, Sze D. Selection between locoregional embolotherapies for hepatic metastases from neuroendocrine tumor: Stratification by tumor burden. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
23
|
AbdelRazek M, Kothary N, Louie J, Sze D. Hepatic abscess after transarterial chemoembolization (TACE): a complication with possible therapeutic effect via serendipitous immunotherapy. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
24
|
Moradzadeh N, Laidlaw G, Salahi M, Jaju P, Louie J, Sze D, Hwang G. No difference in postprocedure complications and reintervention after direct intrahepatic portocaval shunts versus transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.1172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
25
|
Idakoji I, Louie J, Sze D, Wang D. Clinical outcomes after parallel TIPS and DIPS using stent-grafts. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
26
|
Salahi M, Moradzadeh N, Laidlaw G, Jaju P, Sze D, Hwang G, Salahi M. Outcomes of varix embolization and sclerosis in patients undergoing transjugular intrahepatic portosystemic shunt placement for refractory ascites. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
27
|
Laidlaw G, Salahi M, Moradzadeh N, Jaju P, Sze D, Hwang G. Persistent variceal filling on portal venography after transjugular intrahepatic portosystemic shunt creation and the risk of post-TIPS variceal hemorrhage. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
28
|
Laidlaw G, Salahi M, Moradzadeh N, Jaju P, Sze D, Hwang G. Does the location of bleeding varices affect rebleeding risk after transjugular intrahepatic portosystemic shunt placement? J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.1008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
29
|
Wang N, Gallagher R, Sullivan A, Hales S, Sharp P, Hanvey K, Baker V, Sze D, Tofler G. Predictors of Frequent Readmission in Patients with Heart Failure. Heart Lung Circ 2016. [DOI: 10.1016/j.hlc.2016.06.282] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Sheu A, Ang M, Fang A, Sze D, Louie J, Hovsepian D, Hwang G. Off-label intravascular uses of embolic glue: how we avoid sticky situations. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
31
|
Fang A, Crawley A, Sheu A, Ang M, Sze D, Louie J, Hwang G. Accuracy of estimates of treated volume from C-arm cone-beam computed tomography data during partial splenic embolization using N-butyl cyanoacrylate. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
32
|
Chan L, Sze D, Louie J, Wang D. Yttrium-90 radioembolization for unresectable combined hepatocellular-cholangiocarcinoma. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
33
|
Arendt V, Arendt V, Kuo W, Shah R, Kothary N, Wang D, Hovsepian D, Sze D, Louie J, Hwang G, Hofmann L. Twenty years of lower extremity venous stenting experience. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
34
|
Ward T, Shah R, Louie J, Sze D. Yttrium-90 radioembolization using resin microspheres without prophylactic embolization of the gastroduodenal artery. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
35
|
Chen J, Rose S, White S, El-Haddad G, Fidelman N, Yarmohammadi H, Sze D, Kothary N, Stashek K, Wileyto E, Salem R, Metz D, Soulen M. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
36
|
Weiss K, Lungren M, Rangaswami A, Concepcion W, Sze D. The use of transcatheter selective arterial chemoembolization in pediatric patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2016. [DOI: 10.1016/j.jvir.2015.12.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
37
|
|
38
|
Abstract
We administered an adenoviral vector, Onyx-015, into the hepatic artery of patients with metastatic colorectal cancer involving the liver. Thirty-five patients enrolled in this multi-institutional phase I/II trial received up to eight arterial infusions of up to 2 × 1012 viral particles. Hepatic toxicity was the primary dose-limiting toxicity observed in preclinical models. However, nearly 200 infusions of this adenoviral vector were administered directly into the hepatic artery without significant toxicity. Therefore, we undertook this analysis to determine the impact of repeated adenoviral exposure on hepatic function. Seventeen patients were treated at our institution, providing a detailed data set on the changes in hepatic function following repeated exposure to adenovirus. No changes in hepatic function occurred with the first treatment of Onyx-015 among these patients. Transient increases in transaminase levels occurred in one patient starting with the second infusion and transient increases in bilirubin was observed in two patients starting with the fifth treatment. These changes occurred too early to be explained by viral-mediated lysis of hepatocytes. In addition, viremia was observed starting 3–5 days after the viral infusion in half of the patient, but was not associated with hepatic toxicity. To further understand the basis for the minimal hepatic toxicity of adenoviral vectors, we evaluated the replication of adenovirus in primary hepatocytes and tumor cells in culture and the expression of the coxsackie-adenoviral receptor (CAR) in normal liver and colon cancer metastatic to the liver. We found that adenovirus replicates poorly in primary hepatocytes but replicates efficiently in tumors including tumors derived from hepatocytes. In addition, we found that CAR is localized at junctions between hepatocytes and is inaccessible to hepatic blood flow. CAR is not expressed on tumor vasculature but is expressed on tumor cells. Spatial restriction of CAR to the intercellular space in normal liver and diminished replication of adenovirus in hepatocytes may explain the minimal toxicity observed following repeated hepatic artery infusions with Onyx-015.
Collapse
Affiliation(s)
- T Au
- Palo Alto Veteran's Administration Health Care System and Stanford University, Stanford, CA USA
| | - S Thorne
- Palo Alto Veteran's Administration Health Care System and Stanford University, Stanford, CA USA
| | - W M Korn
- University of California, San Francisco, CA USA
| | - D Sze
- Palo Alto Veteran's Administration Health Care System and Stanford University, Stanford, CA USA
| | - D Kirn
- Oxford University, Jennerex Biotherapeutics, San Francisco, CA USA
| | - T R Reid
- Palo Alto Veteran's Administration Health Care System and Stanford University, Stanford, CA USA
| |
Collapse
|
39
|
Sze D, Au T, Thorne S, Sze D, Kirn D, Korn M, Reid T. Minimal hepatic toxicity following infusion of adenoviral vector: Spatial restriction of CAR receptor in normal liver. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Sze
- Stanford Univ, Stanford, CA; Univ of CA, San Diego, La Jolla, CA; Stanford, Stanford, CA; Kirn Consulting, Mill Valley, CA; Univ of CA, San Francisco, San Francisco, CA; Univ of CA, San Francisco, La Jolla, CA
| | - T. Au
- Stanford Univ, Stanford, CA; Univ of CA, San Diego, La Jolla, CA; Stanford, Stanford, CA; Kirn Consulting, Mill Valley, CA; Univ of CA, San Francisco, San Francisco, CA; Univ of CA, San Francisco, La Jolla, CA
| | - S. Thorne
- Stanford Univ, Stanford, CA; Univ of CA, San Diego, La Jolla, CA; Stanford, Stanford, CA; Kirn Consulting, Mill Valley, CA; Univ of CA, San Francisco, San Francisco, CA; Univ of CA, San Francisco, La Jolla, CA
| | - D. Sze
- Stanford Univ, Stanford, CA; Univ of CA, San Diego, La Jolla, CA; Stanford, Stanford, CA; Kirn Consulting, Mill Valley, CA; Univ of CA, San Francisco, San Francisco, CA; Univ of CA, San Francisco, La Jolla, CA
| | - D. Kirn
- Stanford Univ, Stanford, CA; Univ of CA, San Diego, La Jolla, CA; Stanford, Stanford, CA; Kirn Consulting, Mill Valley, CA; Univ of CA, San Francisco, San Francisco, CA; Univ of CA, San Francisco, La Jolla, CA
| | - M. Korn
- Stanford Univ, Stanford, CA; Univ of CA, San Diego, La Jolla, CA; Stanford, Stanford, CA; Kirn Consulting, Mill Valley, CA; Univ of CA, San Francisco, San Francisco, CA; Univ of CA, San Francisco, La Jolla, CA
| | - T. Reid
- Stanford Univ, Stanford, CA; Univ of CA, San Diego, La Jolla, CA; Stanford, Stanford, CA; Kirn Consulting, Mill Valley, CA; Univ of CA, San Francisco, San Francisco, CA; Univ of CA, San Francisco, La Jolla, CA
| |
Collapse
|
40
|
Sze D, Freeman S, Reid TR. Arterial infusion of Onyx-015: Response rate and survival among patients with metastatic colorectal cancer refractory to 5-fu. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Sze
- Stanford University, Palo Alto, CA; Onyx Pharmaceuticals, Richmond, CA; Palo Alto VA/Stanford University, Palo Alto, CA
| | - S. Freeman
- Stanford University, Palo Alto, CA; Onyx Pharmaceuticals, Richmond, CA; Palo Alto VA/Stanford University, Palo Alto, CA
| | - T. R. Reid
- Stanford University, Palo Alto, CA; Onyx Pharmaceuticals, Richmond, CA; Palo Alto VA/Stanford University, Palo Alto, CA
| |
Collapse
|
41
|
Abdou M, TEAM TAPEX, Ying A, Morley N, Gulec K, Smolentsev S, Kotschenreuther M, Malang S, Zinkle S, Rognlien T, Fogarty P, Nelson B, Nygren R, McCarthy K, Youssef M, Ghoniem N, Sze D, Wong C, Sawan M, Khater H, Woolley R, Mattas R, Moir R, Sharafat S, Brooks J, Hassanein A, Petti D, Tillack M, Ulrickson M, Uchimoto T. On the exploration of innovative concepts for fusion chamber technology. Fusion Engineering and Design 2001. [DOI: 10.1016/s0920-3796(00)00433-6] [Citation(s) in RCA: 254] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kirn D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001; 8:1618-26. [PMID: 11895000 PMCID: PMC7092315 DOI: 10.1038/sj.gt.3301512] [Citation(s) in RCA: 181] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Both replication-incompetent and replication-selective adenoviruses are being developed for the treatment of cancer and other diseases. Concerns have been raised about the safety of intra-vascular adenovirus administration following a patient death on a clinical trial with a replication-defective adenovirus. In addition, the feasibility of vascular delivery to distant tumors has been questioned. dl1520 (ONYX-015) is a replication-selective adenovirus that has previously shown safety and antitumoral activity following intratumoral injection. This is the first report of intra-vascular administration with a genetically engineered, replication-selective virus. A phase I dose-escalation trial was performed in patients with liver-predominant gastrointestinal carcinoma (n = 11 total; primarily colorectal). dl1520 was infused into the hepatic artery at doses of 2 x 10(8)-2 x 10(1)2 particles for two cycles (days 1 and 8). Subsequent cycles of dl1520 were administered in combination with intravenous 5-fluorouracil (5-FU) and leucovorin. No dose-limiting toxicity, maximally tolerated dose or treatment-emergent clinical hepatotoxicity were identified following dl1520 infusion. Mild to moderate fever, rigors and fatigue were the most common adverse events. Antibody titers increased significantly in all patients. Viral replication was detectable in patients receiving the highest two doses. An objective response was demonstrated in combination with chemotherapy in a patient who was refractory to both 5-FU and dl1520 as single agents. Therefore, hepatic artery infusion of the attenuated adenovirus dl1520 was well-tolerated at doses resulting in infection, replication and chemotherapy-associated antitumoral activity.
Collapse
Affiliation(s)
- T Reid
- Palo Alto Veterans Administration Hospital and Stanford University Medical Center, Palo Alto, CA USA
| | | | | | - D Sze
- Palo Alto Veterans Administration Hospital and Stanford University Medical Center, Palo Alto, CA USA
| | | | - L Romel
- Onyx Pharmaceuticals, Richmond, CA USA
| | | | - J Rubin
- Mayo Clinic, Rochester, MN USA
| | - D Kirn
- Imperial Cancer Research Fund, Imperial College School of Medicine, London, UK
| |
Collapse
|
43
|
Mattas R, Allain J, Bastasz R, Brooks J, Evans T, Hassanein A, Luckhardt S, McCarthy K, Mioduszewski P, Maingi R, Mogahed E, Moir R, Molokov S, Morely N, Nygren R, Rognlien T, Reed C, Ruzic D, Sviatoslavsky I, Sze D, Tillack M, Ulrickson M, Wade P, Wooley R, Wong C. ALPS–advanced limiter-divertor plasma-facing systems. Fusion Engineering and Design 2000. [DOI: 10.1016/s0920-3796(00)00385-9] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Raitakari M, Brown RD, Sze D, Yuen E, Barrow L, Nelson M, Pope B, Esdale W, Gibson J, Joshua DE. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol 2000; 110:203-9. [PMID: 10930999 DOI: 10.1046/j.1365-2141.2000.02131.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The presence of T-cell clones in peripheral blood has been previously shown to be associated with a survival advantage in patients with multiple myeloma and suggests that the expanded T-cell populations may be involved in an anti-tumour response. We studied the T-cell receptor (TCR) repertoire of 38 patients with myeloma to identify and characterize the expanded T-cell populations by flow cytometry. T-cell expansions were found in 79% of the patients. The expansions occurred randomly among the 21 variable regions of the TCR beta chain (Vbeta) studied, representing 62% of the V-beta repertoire, and were stable during an 18-month follow-up. The phenotype of the expanded V-beta populations was predominantly CD8+, CD57+, CD28- and perforin+, which differed significantly from the other non-expanded Vbeta populations. The expression of the apoptosis markers Fas (CD95) and bcl-2 were similar between the expanded and non-expanded Vbeta populations. In conclusion, expanded T-cell populations were frequent in patients with myeloma, they remained unchanged during follow-up and had phenotypic characteristics of cytotoxic T cells. These data add further support to the concept that the T-cell expansions may have an immunoregulatory role in myeloma.
Collapse
Affiliation(s)
- M Raitakari
- Department of Clinical Chemistry, Turku University Central Hospital, Finland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Razavi MK, DeGroot M, Olcott C, Sze D, Kee S, Semba CP, Dake MD. Internal iliac artery embolization in the stent-graft treatment of aortoiliac aneurysms: analysis of outcomes and complications. J Vasc Interv Radiol 2000; 11:561-6. [PMID: 10834485 DOI: 10.1016/s1051-0443(07)61606-6] [Citation(s) in RCA: 133] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE To analyze the complications of internal iliac artery (IIA) embolization in conjunction with stent-graft treatment of aortoiliac aneurysms. MATERIALS AND METHODS Seventy-one patients with aortoiliac (n = 47) or iliac (n = 24) aneurysms were treated with endoluminal placement of stent-grafts. Thirty-two patients (31 men, one woman; mean age, 73 years; range, 56-88 years) had embolization or occlusion of one (n = 27) or both (n = 5) IIAs. Status of the IIAs and the collateral circulation was assessed by retrospective review of angiographic images. Follow-up consisted of a standardized patient questionnaire and review of radiologic and medical records. RESULTS The mean follow-up time was 35 months (range, 5-64 months). Eleven of the 47 patients with abdominal aortic aneurysms (AAA) (23%) and 19 of the 24 patients with iliac aneurysms (79%) required IIA embolization. One patient with AAA and another with iliac aneurysm had unintentional occlusion of an IIA by extension of the stent-graft over their origins. A total of seven patients had bilateral occlusion of the IIAs after the procedure. Additionally, the inferior mesenteric arteries (IMAs) of two other patients with AAA were also embolized. In six patients, all three vessels were occluded after placement of the stent-grafts. Symptoms were reported in nine of the 20 (45%) patients with iliac aneurysms and in three of the 12 (25%) patients with AAA. Symptoms consisted of buttock claudication (nine of 32, 28%), new sexual dysfunction (two of 16, 12%), and transient urinary retention (3%). Seven of the claudicants had resolution of symptoms after a mean interval of 14 months (range, 1-36 months). There were no instances of bowel ischemia, neurologic sequelae, or buttock necrosis related to these procedures. CONCLUSION Embolization of the IIA is associated with symptoms in a significant number of patients. While symptoms are transient in most patients, they can be problematic. Efforts should be made to preserve the pelvic circulation if possible.
Collapse
Affiliation(s)
- M K Razavi
- Section of Cardiovascular & Interventional Radiology, Stanford University Hospital, California 94305, USA.
| | | | | | | | | | | | | |
Collapse
|
46
|
|
47
|
McMorrow I, Shuman HA, Sze D, Wilson DM, Wilson TH. Sodium/proton antiport is required for growth of Escherichia coli at alkaline pH. Biochim Biophys Acta 1989; 981:21-6. [PMID: 2541789 DOI: 10.1016/0005-2736(89)90077-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Evidence is presented indicating that Escherichia coli requires the Na+/H+ antiporter and external sodium (or lithium) ion to grow at high pH. Cells were grown in plastic tubes containing medium with a very low Na+ content (5-15 microM). Normal cells grew at pH 7 or 8 with or without added Na+, but at pH 8.5 external Na was required for growth. A mutant with low antiporter activity failed to grow at pH 8.5 with or without Na+. On the other hand, another mutant with elevated antiporter activity grew at a higher pH than normal (pH 9) in the presence of added Na+ or Li+. Amiloride, an inhibitor of the antiporter, prevented cells from growing at pH 8.5 (plus Na+), although it had no effect on growth in media of lower pH values.
Collapse
Affiliation(s)
- I McMorrow
- Department of Cellular and Molecular Physiology, Harvard Medical School, Boston, MA 02115
| | | | | | | | | |
Collapse
|